Saturday, 14 December 2013

Specialist Product Advisors Latest career Vacancy At Novo Nordisk In Nigeria 2014


Specialist Product Advisors Latest Vacancy At Novo Nordisk In Nigeria
Novo Nordisk Middle Africa unit covers approximately 800 million people across 48 countries. Novo Nordisk has an established presence with Human Insulin and Modern Insulin in Africa and our focus today is to sustain the growth of the market, ensure availability of better quality Modern Insulin within the markets and support the communities living with diabetes. Novo Nordisk Nigeria is a part of Middle Africa unit and we are looking to expand our reach in the country.
Novo Nordisk Nigeria is looking to fill the following position:
Job Title: Specialist Product Advisors (Medical Representatives)
Location will be based in Cross Rivers, Enugu, Kogi, Kano, Lagos, Port Harcourt, Ibadan, Abuja, Kaduna, Akure reporting to the Sales Supervisor.
Responsibilities
Executing sales with an indispensable business ethical mind-set
Establishing a data base of HCPs and KOLs
One on one detailing to doctors & other HCPs
Organising continuing medical education (CME) sessions for HCPs
Securing sales and business growth in the territory
Securing public tenders
Establishing a consultative relationship with customers
Obtaining, utilizing, and communicating market information effectively.
Qualifications
Bachelor’s degree in Pharmacy, Pharmacology, Biochemistry or Microbiology.
2 years’ experience in promoting pharmaceutical products
Pharmaceutical market knowledge
Professional sales qualification is an added advantage
Application Closing Date
24th December, 2013
Method of Application
Interested and qualified candidates should send your CV to Olatunbosun Odutayo at: ooy@novonordisk.com
Note: The expected employment date is 1st February, 2014. Kindly indicate which location or locations you are applying for in the title of the application e-mail e.g. ‘Application for Medical Representative- Akure, Lagos, Kano.
Applications which do not indicate the location preference, will not be taken into consideration.

No comments:

Post a Comment